PharmacoEconomics

1997 - 2024

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 42, issue 12, 2024

Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning pp. 1301-1315

Paul Crosland, Deborah A. Marshall, Seyed Hossein Hosseini, Nicholas Ho, Catherine Vacher, Adam Skinner, Kim-Huong Nguyen, Frank Iorfino, Sebastian Rosenberg, Yun Ju Christine Song, Apostolos Tsiachristas, Kristen Tran, Jo-An Occhipinti and Ian B. Hickie

MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial pp. 1317-1327

Ash Bullement, Mark Edmondson-Jones, Patricia Guyot, Nicky J. Welton, Gianluca Baio, Matthew Stevenson and Nicholas R. Latimer

Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review pp. 1329-1343

Ippazio Cosimo Antonazzo, Giorgia Gribaudo, Adriano Vecchia, Pietro Ferrara, Alexandra Piraino, Paolo Angelo Cortesi and Lorenzo Giovanni Mantovani

Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study pp. 1345-1357

Meiyu Wu, Jing Ma, Sini Li, Shuxia Qin, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G. Lim and Xiaomin Wan

Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care pp. 1359-1371

Amy Gye, Richard Abreu Lourenco and Stephen Goodall

Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias pp. 1373-1394

Yankier Pijeira Perez and Dyfrig A. Hughes

An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail? pp. 1395-1412

Nicholas R. Latimer, Kurt Taylor, Anthony J. Hatswell, Sophia Ho, Gabriel Okorogheye, Clara Chen, Inkyu Kim, John Borrill and David Bertwistle

Valuation of the EORTC Quality of Life Utility Core 10 Dimensions (QLU-C10D) in a Multi-ethnic Asian Setting: How Does Having Cancer Matter? pp. 1413-1425

Mihir Gandhi, Ravindran Kanesvaran, Mohamad Farid Bin Harunal Rashid, Dawn Qingqing Chong, Wen-Yee Chay, Rachel Lee-Yin Tan, Richard Norman, Madeleine T. King and Nan Luo

Volume 42, issue 11, 2024

Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective pp. 1177-1179

Keith Cooper, Emma Maund, Marcia Tomie Takahashi and Jonathan Shepherd

Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling pp. 1181-1196

Kurt Taylor, Nicholas R. Latimer, Thomas Douglas, Anthony J. Hatswell, Sophia Ho, Gabriel Okorogheye, John Borril, Clara Chen, Inkyu Kim and David Bertwistle

Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD) pp. 1197-1208

Jeff Round, Erin Kirwin, Sasha Katwyk and Christopher McCabe

Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses pp. 1209-1236

Ewan M. Tomeny, Thomas Hampton, Phuong Bich Tran, Laura Rosu, Mphatso D. Phiri, Kathryn A. Haigh, Jasper Nidoi, Tom Wingfield and Eve Worrall

Delaying Oral Anticoagulants: A False Economy? pp. 1237-1239

Brendan Collins and Gregory Y. H. Lip

Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial Fibrillation pp. 1241-1253

Ryan J. Mulholland, Giorgio Ciminata, Terry J. Quinn, Kevin G. Pollock, Steven Lister and Claudia Geue

Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling pp. 1255-1266

Johanna Lister, Suzy Paisley, Christopher Carroll and Paul Tappenden

Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study pp. 1267-1277

Cameron Morgan, Cam Donaldson, Emily Lancsar, Stavros Petrou and Lazaros Andronis

Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program pp. 1279-1286

Snigdha Gulati, Mohak Gupta, TingTing Yan, Sneha Yelamanchili, Lucy Qinghua Xu, Tina Bharani, Ali Naji and Divyansh Agarwal

Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee pp. 1287-1300

Zachary Tirrell, Alicia Norman, Martin Hoyle, Sean Lybrand and Bonny Parkinson

Volume 42, issue 10, 2024

Proxy Preferences and the Values of Children’s Health States pp. 1065-1072

Daniel M. Hausman

Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know pp. 1073-1090

Nicholas R. Latimer and Mark J. Rutherford

Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer pp. 1091-1110

Shikha Sharma, Niamh Carey, David McConnell, Maeve Lowery, Jacintha O’Sullivan and Laura McCullagh

Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model pp. 1111-1125

Yawen Jiang, Jiaxin Wen, Jiatong Sun and Yuelong Shu

Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework pp. 1127-1144

R. Douglas Scott, Steven D. Culler, James Baggs, Sujan C. Reddy, Kara Jacobs Slifka, Shelley S. Magill, Sophia V. Kazakova, John A. Jernigan, Richard E. Nelson, Robert Rosenman and Philip R. Wandschneider

Unravelling Elements of Value of Healthcare and Assessing their Importance Using Evidence from Two Discrete-Choice Experiments in England pp. 1145-1159

Pamela Gongora-Salazar, Rafael Perera, Oliver Rivero-Arias and Apostolos Tsiachristas

A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist pp. 1161-1175

Jemimah Ride, Ilias Goranitis, Yan Meng, Christine LaBond and Emily Lancsar

Volume 42, issue 9, 2024

NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective pp. 913-917

Najmeh Moradi, Nicole O’Connor, Katie H. Thomson, Hosein Shabaninejad, Tumi Sotire, Madeleine Still, Cristina Fernandez-Garcia, Sheila A. Wallace, Oleta Williams, Luke Vale and Gurdeep S. Sagoo

Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation pp. 919-928

David Glynn, Vijay Gc, Karl Claxton, Chris Littlewood and Claire Rothery

Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data pp. 929-953

Lisa A. Jong, Xinyu Li, Sajad Emamipour, Sjoukje Werf, Maarten J. Postma, Peter R. Dijk and Talitha L. Feenstra

A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models pp. 955-1002

Andreas Freitag, Grammati Sarri, An Ta, Laura Gurskyte, Dasha Cherepanov and Luis G. Hernandez

A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies pp. 1003-1016

Paul Tappenden, Orla Hardiman, Sun-Hong Kwon, Mon Mon-Yee, Miriam Galvin and Christopher McDermott

Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management pp. 1017-1028

Ni Gao, Helen A. Dakin, Rury R. Holman, Lee-Ling Lim, José Leal and Philip Clarke

Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia pp. 1029-1045

Andrew J. Sutton, Daniel S. Lupu, Stephen P. Bergin, Thomas L. Holland, Staci A. McAdams, Sanjeet S. Dadwal, Khoi Nguyen, Frederick S. Nolte, Gabriel Tremblay and Bradley A. Perkins

Estimating an EQ-5D-Y-3L Value Set for Brazil pp. 1047-1063

Caique Melo Espirito Santo, Gisela Cristiane Miyamoto, Verônica Souza Santos, Ângela Jornada Ben, Aureliano Paolo Finch, Bram Roudijk, Fabianna Resende Jesus-Moraleida, Airton Tetelbom Stein, Marisa Santos and Tiê Parma Yamato

Volume 42, issue 8, 2024

Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs? pp. 823-827

Salah Ghabri

Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective pp. 829-832

Mirre Scholte, Bram Ramaekers, Evangelos Danopoulos, Sabine E. Grimm, Andrea Fernandez Coves, Xiaoyu Tian, Thomas Debray, Jiongyu Chen, Lisa Stirk, Rachel Croft, Manuela Joore and Nigel Armstrong

A Prototype Software Framework for Transferable Computational Health Economic Models and Its Early Application in Youth Mental Health pp. 833-842

Matthew P. Hamilton, Caroline Gao, Glen Wiesner, Kate M. Filia, Jana M. Menssink, Petra Plencnerova, David G. Baker, Patrick D. McGorry, Alexandra Parker, Jonathan Karnon, Sue M. Cotton and Cathrine Mihalopoulos

A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses pp. 843-863

Ramesh Lamsal, E. Ann Yeh, Eleanor Pullenayegum and Wendy J. Ungar

A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries pp. 865-877

Ery Setiawan, Sarah A. Cassidy-Seyoum, Kamala Thriemer, Natalie Carvalho and Angela Devine

Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision pp. 879-894

Anne Bruijn, Mats Don, Saskia Knies, Werner Brouwer and Vivian Reckers-Droog

Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries pp. 895-909

Laura Panattoni, Mairead Kearney, Natalie Land, Thomas Flottemesch, Patrick Sullivan, Melissa Kirker, Murtuza Bharmal and Brett Hauber

Correction to: Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries pp. 911-911

Laura Panattoni, Mairead Kearney, Natalie Land, Thomas Flottemesch, Patrick Sullivan, Melissa Kirker, Murtuza Bharmal and Brett Hauber

Volume 42, issue 7, 2024

Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling pp. 715-719

Isaac Corro Ramos, Talitha Feenstra, Salah Ghabri and Maiwenn Al

Bayesian Meta-Analysis of Health State Utility Values: A Tutorial with a Practical Application in Heart Failure pp. 721-735

Joseph Alvin Ramos Santos, Robert Grant and Gian Luca Di Tanna

Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature pp. 737-749

Gemma E. Shields, Paul Clarkson, Ash Bullement, Warren Stevens, Mark Wilberforce, Tracey Farragher, Arpana Verma and Linda M. Davies

Cost-of-Illness of Skin Cancer: A Systematic Review pp. 751-765

Annick Meertens, Laura Coile, Tijs Iseghem, Lieve Brochez, Nick Verhaeghe and Isabelle Hoorens

Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations pp. 767-782

Muchandifunga Trust Muchadeyi, Karla Hernandez-Villafuerte, Gian Luca Tanna, Rachel D. Eckford, Yan Feng, Michela Meregaglia, Tessa Peasgood, Stavros Petrou, Jasper Ubels and Michael Schlander

Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results pp. 783-795

Yanara Marks, Jeffrey S. Hoch, Anna Heath and Petros Pechlivanoglou

A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations pp. 797-810

Junfeng Wang, Xavier Pouwels, Bram Ramaekers, Geert Frederix, Chris Lieshout, Rudolf Hoogenveen, Xinyu Li, G. Ardine Wit, Manuela Joore, Hendrik Koffijberg, Anoukh Giessen, Saskia Knies and Talitha Feenstra

Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective pp. 811-822

Takao Takeshima, Fumihiko Sakai, Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, Yilong Zhang, Craig Bennison and Martijn J. H. G. Simons

Volume 42, issue 6, 2024

Market Transparency in Medicine Pricing: Pathways to Fair Pricing pp. 611-614

João L. Carapinha

Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective pp. 615-618

Bradley M. Sugden, Sabine E. Grimm, Robert Wolff, Nigel Armstrong, Thomas Otten, Teebah Abu-Zahra, Mark Perry, Mubarak Patel, Jiongyu Chen, Caro Noake, Manuela Joore and Willem J. A. Witlox

Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review pp. 619-631

Tobias Sydendal Grand, Shijie Ren, James Hall, Daniel Oudin Åström, Stephane Regnier and Praveen Thokala

Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review pp. 633-647

Clazinus Veijer, Marinus H. Hulst, Benjamin Friedrichson, Maarten J. Postma and Antoinette D.I. Asselt

Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study pp. 649-661

Olu Onyimadu, Nerys M. Astbury, Felix Achana, Stavros Petrou and Mara Violato

Developing a Program Costs Checklist of Digital Health Interventions: A Scoping Review and Empirical Case Study pp. 663-678

Zareen Abbas Khan, Kristian Kidholm, Sindre Andre Pedersen, Silje Marie Haga, Filip Drozd, Thea Sundrehagen, Ellen Olavesen and Vidar Halsteinli

Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective? pp. 679-691

Anna Kenseth, Dominika Kantorova, Mikyung Kelly Seo, Eline Aas, John Cairns, David Kerr, Hanne Askautrud and Jørn Evert Jacobsen

Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States pp. 693-714

William L. Herring, Meghan E. Gallagher, Nirmish Shah, Morse Kc, Deirdre Mladsi, Olivia M. Dong, Anjulika Chawla, Jennifer W. Leiding, Lixin Zhang, Clark Paramore and Biree Andemariam

Volume 42, issue 5, 2024

Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap pp. 475-478

Erik Landfeldt and Hera Sandhu

Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators pp. 479-486

Anna Heath, Gianluca Baio, Ioanna Manolopoulou and Nicky J. Welton

Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments pp. 487-506

Jen-Yu Amy Chang, James B. Chilcott and Nicholas R. Latimer

Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review pp. 507-526

Billingsley Kaambwa, Taylor-Jade Woods, Andrea Natsky, Norma Bulamu, Christine Mpundu-Kaambwa, Kelly A. Loffler, Alexander Sweetman, Peter G. Catcheside, Amy C. Reynolds, Robert Adams and Danny J. Eckert

Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review pp. 527-568

Angie Raad, Maria Rizzo, Katherine Appiah, Isabella Kearns and Luis Hernandez

Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA pp. 569-582

Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu, Eunice Kim and Matthew Matasar

Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary pp. 583-603

Anna Nikl, Mathieu F. Janssen, Balázs Jenei, Valentin Brodszky and Fanni Rencz

Comment on: A Framework for the Fair Pricing of Medicines pp. 605-606

Zaheer-Ud-Din Babar

Reply to Comment on “A Framework for Fair Pricing of Medicines” pp. 607-609

Mike Paulden

Volume 42, issue 4, 2024

A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework pp. 363-371

Natalia Kunst, Emily A. Burger, Veerle M. H. Coupé, Karen M. Kuntz and Eline Aas

Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review pp. 373-392

Clara Marquina, Jedidiah I Morton, Melanie Lloyd, Dina Abushanab, Yeji Baek, Tamrat Abebe, Adam Livori, Padam Dahal, Gerald F. Watts and Zanfina Ademi

An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada pp. 393-407

Diedron Lewis, William W. L. Wong, Joseph Lipscomb and Susan Horton

Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia pp. 409-418

Dong-Won Kang, Li Wang, Nicholas J. Short, Alessandra Ferrajoli, Yucai Wang, Shouhao Zhou and Chan Shen

Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy pp. 419-434

Zakile A. Mfumbilwa, Martijn J. H. G. Simons, Bram Ramaekers, Valesca P. Retèl, Joanne M. Mankor, Harry J. M. Groen, Joachim G. J. V. Aerts, Manuela Joore, Janneke A. Wilschut and Veerle M. H. Coupé

The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life pp. 435-446

Cate Bailey, Martin Howell, Rakhee Raghunandan, Kim Dalziel, Kirsten Howard, Brendan Mulhern, Stavros Petrou, Donna Rowen, Amber Salisbury, Rosalie Viney, Emily Lancsar and Nancy Devlin

Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States pp. 447-461

Anita J. Brogan, Ashley E. Davis, Claire E. Mellott, Jeremy Fraysse, Aimee A. Metzner and Alan K. Oglesby

The Burden of Type 2 Diabetes on the Productivity and Economy in Sub-Saharan Africa: A Life Table Modelling Analysis from a South African Perspective pp. 463-473

Assegid Hellebo, Andre P. Kengne, Zanfina Ademi and Olufunke Alaba

Volume 42, issue 3, 2024

Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement pp. 249-252

Stephanie Harvard

A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments pp. 253-259

T. Joseph Mattingly

Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial pp. 261-273

Junwen Zhou, Claire Williams, Mi Jun Keng, Runguo Wu and Borislava Mihaylova

Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review pp. 275-299

Lucinda J. Teoh, Salomey Kellett, Dipesh E. Patel, Mario Cortina-Borja, Ameenat Lola Solebo and Jugnoo S. Rahi

Palliative Care Costs in Different Ambulatory-Based Settings: A Systematic Review pp. 301-318

Ana Helena Perea-Bello, Marta Trapero-Bertran and Christian Dürsteler

Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid pp. 319-328

Antal Zemplenyi, Jim Leonard, Michael J. DiStefano, Kelly E. Anderson, Garth C. Wright, Nicholas D. Mendola, Kavita Nair and R. Brett McQueen

Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study pp. 329-341

Jason Gordon, Maria Gheorghe, Cale Harrison, Ryan Miller, James Dennis, Lotte Steuten, Simon Goldenberg, Sumanth Gandra and Amer Al-Taie

Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force pp. 343-362

Edward Henry, Hareth Al-Janabi, Werner Brouwer, John Cullinan, Lidia Engel, Susan Griffin, Claire Hulme, Pritaporn Kingkaew, Andrew Lloyd, Nalin Payakachat, Becky Pennington, Luz María Peña-Longobardo, Lisa A. Prosser, Koonal Shah, Wendy J. Ungar, Thomas Wilkinson and Eve Wittenberg

Volume 42, issue 2, 2024

Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective pp. 133-136

Giovany Orozco-Leal, Eugenie Evelynne Johnson, Sedighe Hosseinijebeli, Tomos Robinson, Tara Homer, Claire H. Eastaugh, Catherine Richmond, Louise Tanner, Nick Meader, Ryan Kenny, Sheila A. Wallace and Stephen Rice

Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum pp. 137-144

Daniel Gladwell, Oriana Ciani, Adam Parnaby and Stephen Palmer

A Framework for the Fair Pricing of Medicines pp. 145-164

Mike Paulden

Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments pp. 165-176

Alex J. Turner, Cormac Sammon, Nick Latimer, Blythe Adamson, Brennan Beal, Vivek Subbiah, Keith R. Abrams and Joshua Ray

Systematic Review of the Relative Social Value of Child and Adult Health pp. 177-198

Tessa Peasgood, Martin Howell, Rakhee Raghunandan, Amber Salisbury, Marcus Sellars, Gang Chen, Joanna Coast, Jonathan C. Craig, Nancy J. Devlin, Kirsten Howard, Emily Lancsar, Stavros Petrou, Julie Ratcliffe, Rosalie Viney, Germaine Wong, Richard Norman and Cam Donaldson

Advancing Methods to Measure and Reward Healthcare Innovation pp. 183-185

Richard Chapman and Richard Xie

The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment pp. 187-197

Frederick McElwee and Anthony Newall

Incorporating Real Option Value in Valuing Innovation: A Way Forward pp. 199-210

Meng Li and Louis P. Garrison

A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects pp. 199-217

Ramesh Lamsal, E. Ann Yeh, Eleanor Pullenayegum and Wendy J. Ungar

Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework pp. 211-224

Askal Ayalew Ali, Amit Kulkarni, Sandipan Bhattacharjee and Vakaramoko Diaby

Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study pp. 219-229

Javier Mar, Oliver Ibarrondo, Carlo Delfin S. Estadilla, Nico Stollenwerk, Fernando Antoñanzas, Rubén Blasco-Aguado, Igor Larrañaga, Joseba Bidaurrazaga and Maíra Aguiar

Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States pp. 231-247

Christopher W. Yee, Michael J. Harvey, Yiqiao Xin and Noam Y. Kirson

Volume 42, issue 1, 2024

Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children pp. 3-8

Wendy J. Ungar and Michael Herdman

Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective pp. 5-9

Diarmuid Coughlan, Oluwatomi Arisa, Katie Thomson, Ge Yu, Fiona Pearson, Ashleigh Kernohan, Sonia Garcia Gonzalez-Moral, Sheila Wallace and Stephen Rice

Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review pp. 9-37

Christine Mpundu-Kaambwa, Norma B. Bulamu, Lauren Lines, Gang Chen, David G. T. Whitehurst, Kim Dalziel, Nancy Devlin and Julie Ratcliffe

The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations pp. 11-18

Daniel Hill-McManus

A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus pp. 19-40

Marina Antoniou, Ceu Mateus, Bruce Hollingsworth and Andrew Titman

Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Study pp. 39-55

Renee Jones, Rachel O’Loughlin, Xiuqin Xiong, Mina Bahrampour, Nancy Devlin, Harriet Hiscock, Gang Chen, Brendan Mulhern and Kim Dalziel

Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis pp. 41-68

Melissa Lannon, Taylor Duda, Alexander Mastrolonardo, Ellissa Huang, Amanda Martyniuk, Forough Farrokhyar, Feng Xie, Mohit Bhandari, Suneil K. Kalia and Sunjay Sharma

Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression pp. 57-77

Rachel O’Loughlin, Renee Jones, Gang Chen, Brendan Mulhern, Harriet Hiscock, Nancy Devlin and Kim Dalziel

Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada pp. 69-90

Aneeka Hafeez, Lauren E. Cipriano, Richard B. Kim, Gregory S. Zaric, Ute I. Schwarz and Sisira Sarma

Correction: Comparing the Psychometric Performance of Generic Paediatric Health‑Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression pp. 79-79

Rachel O’Loughlin, Renee Jones, Gang Chen, Brendan Mulhern, Harriet Hiscock, Nancy Devlin and Kim Dalziel

Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis pp. 81-94

Mina Bahrampour, Renee Jones, Kim Dalziel, Nancy Devlin and Brendan Mulhern

Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis pp. 91-107

Jedidiah I. Morton, Clara Marquina, Melanie Lloyd, Gerald F. Watts, Sophia Zoungas, Danny Liew and Zanfina Ademi

A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data pp. 95-111

Mina Bahrampour, Nancy Devlin, Renee Jones, Kim Dalziel and Brendan Mulhern

Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer pp. 109-116

Anthony J. Hatswell, Mohammad A. Chaudhary, Giles Monnickendam, Alejandro Moreno-Koehler, Katie Frampton, James W. Shaw, John R. Penrod and Rachael Lawrance

An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L pp. 113-128

Diana Khanna, Jyoti Khadka, Christine Mpundu-Kaambwa, Gang Chen, Kim Dalziel, Nancy Devlin and Julie Ratcliffe

Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition pp. 117-131

Daniel Tobias Michaeli and Thomas Michaeli

Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds pp. 129-145

Alexander Heusden, Oliver Rivero-Arias, Michael Herdman, Harriet Hiscock, Nancy Devlin and Kim Dalziel

Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2–4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL) pp. 147-161

Xiuqin Xiong, Natalie Carvalho, Li Huang, Gang Chen, Renee Jones, Nancy Devlin, Brendan Mulhern and Kim Dalziel

The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions pp. 163-179

Cate Bailey, Kim Dalziel, Renee Jones, Harriet Hiscock, Nancy J. Devlin and Tessa Peasgood